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A highly glycosylated, trimeric envelope glycoprotein
(Env) mediates HIV-1 cell entry. The high density and
heterogeneity of the glycans shield Env from recog-
nition by the immune system, but paradoxically,
many potent broadly neutralizing antibodies (bNAbs)
recognize epitopes involving this glycan shield.
To better understand Env glycosylation and its role
in bNAb recognition, we characterized a soluble,
cleaved recombinant trimer (BG505 SOSIP.664) that
is a close structural and antigenic mimic of native
Env. Large, unprocessed oligomannose-type struc-
tures (Man8-9GlcNAc2) are notably prevalent on
the gp120 components of the trimer, irrespective of
the mammalian cell expression system or the bNAb
used for affinity purification. In contrast, gp41 sub-
units carry more highly processed glycans. The gly-
cans on uncleaved, non-native oligomeric gp140
proteins are also highly processed. A homogeneous,
oligomannose-dominated glycan profile is therefore
a hallmark of a native Env conformation and a poten-
tial Achilles’ heel that can be exploited for bNAb
recognition and vaccine design.
INTRODUCTION
The HIV-1 envelope glycoprotein (Env) is a trimer of gp120-gp41
heterodimers that mediates viral entry into host cells (Liu et al.,
2008). As the sole target of broadly neutralizing antibodies1604 Cell Reports 11, 1604–1613, June 16, 2015 ª2015 The Authors(bNAbs) (Hessell et al., 2009; Mascola et al., 2000; Moldt et al.,
2012), it is likely that an effective prophylactic vaccine against
HIV-1 will include a recombinant protein based on the Env trimer.
Given that the trimer is approximately half carbohydrate by
mass (Lasky et al., 1986), an important consideration for the
antigenicity, and perhaps also the immunogenicity, of a recom-
binant version is the extent to which its glycans resemble and
function like those on viral Env. The enormous relevance of gly-
cans in HIV-1 vaccine design is underscored by the isolation of
numerous distinct families of potent bNAbs whose binding is
dependent on Env glycans (Blattner et al., 2014; Falkowska
et al., 2014; Garces et al., 2014; Huang et al., 2014; Kong
et al., 2013; McLellan et al., 2011; Mouquet et al., 2012; Pancera
et al., 2013; Pejchal et al., 2011; Scharf et al., 2014; Walker et al.,
2009, 2011).
Studies on monomeric gp120 proteins have consistently iden-
tified twomajor subgroups of glycan structures: underprocessed
oligomannose and processed complex glycans (Bonomelli et al.,
2011; Doores et al., 2010; Go et al., 2013; Leonard et al., 1990;
Raska et al., 2010). The underprocessed glycans contain multi-
ple terminal mannose sugars (typically five to nine, referred to
as Man5GlcNAc2 to Man9GlcNAc2). Underprocessed glycans
are, therefore, often referred to as ‘‘high-mannose’’ or ‘‘oligo-
mannose’’ glycans (we prefer hereon to use the latter term).
During processing in the endoplasmic reticulum (ER) and early
Golgi apparatus, a-mannosidase enzymes remove a subset of
mannose moieties before various other carbohydrate compo-
nents are added, predominantly in the medial and late Golgi, to
create complex glycans. Whether an oligomannose glycan is
then further modified is not a random event; it is determined by
the spatial location and accessibility of the glycan site on the
folded protein. The dominant factor is most probably whether
Figure 1. Comparison of Glycosylation Patterns of BG505 SOSIP.664
Trimers Produced in CHO and 293T Cells
(A–C) HILIC-UPLC spectra of fluorescently labeled N-linked glycans isolated
from (A) the entire trimeric gp120/gp41ECTO complex (gp140) and the (B) gp120
and (C) gp41ECTO subunits of BG505 SOSIP.664 trimers. The subunits
analyzed in each case are illustrated on the left. Trimers were purified by 2G12-
affinity chromatography followed by SEC. The gp140 bandwas extracted from
a non-reducing SDS-PAGE gel, while the gp120 and gp41ECTO bands were
resolved by SDS-PAGE under reducing conditions. The glycan contents of
proteins extracted from the bands were analyzed. Peaks corresponding to
oligomannose glycans (M5-M9; Man5-9GlcNAc2) are colored in shades of
green; the remaining peaks (gray) correspond to complex and hybrid-type
glycans. Peak areas (as a percentage of total glycans) are illustrated in
the associated pie charts. Glycan structures are represented according to
the color scheme established by the Consortium for Functional Glycomics
(http://www.functionalglycomics.org/). The SOSIP.664 construct contains the
following mutations: a T332N mutation to introduce the 332 glycosylation site,
cysteines at 501 and 605 form a disulphide bridge to covalently link the gp120
and gp41ECTO subunits, replacement of the gp120 furin cleavage site (REKR)
with a hexa-arginine (R6) sequence to promote furin cleavage, an I559P mu-
tation to stabilize the gp41ECTO subunits in the prefusion form, and deletion of
the MPER region at residue 664 to reduce aggregation.a-mannosidases can gain access to their substrates since un-
processed glycans are sterically shielded by other glycans
and/or the protein backbone. The unprocessed glycans in
HIV-1 Env tend to be clustered in the ‘‘intrinsic mannose patch’’
(IMP), thereby creating a large exposed surface of conserved
glycans that can be targeted by bNAbs and that contains
multiple overlapping epitopes (Calarese et al., 2003; Garces
et al., 2014; Kong et al., 2013; Mouquet et al., 2012; Murin
et al., 2014; Sanders et al., 2002; Scanlan et al., 2002; Walker
et al., 2009, 2011).
Glycan characterization of native, virion-derived trimers re-
mains a challenge due to difficulties in obtaining a sample suffi-Cecient for analysis, due in large part to the very limited numbers of
Env proteins on the viral surface. Previous studies have con-
firmed the presence of an IMP on virion-derived gp120; however,
further investigation, including characterization of gp41 glycosyl-
ation, was not possible (Bonomelli et al., 2011; Doores et al.,
2010). In this study, we have investigated the glycosylation of
a highly purified, recombinant, soluble Env trimer, BG505
SOSIP.664. These trimers closely mimic the structure and anti-
genicity of native, virion-associated Env, and their high-resolu-
tion EM and crystal structures have been determined (Julien
et al., 2013; Lyumkis et al., 2013; Pancera et al., 2014; Sanders
et al., 2013). We have quantified the glycan composition of
BG505 SOSIP.664 trimers expressed in several cell types and
purified in different ways, in comparison with other forms of
recombinant Env that are being considered as candidate HIV-1
vaccines. Our results show that gp120 subunits from BG505
SOSIP.664 trimers contain a homogeneous glycan profile
that is characterized by a high abundance of the largest oligo-
mannose-type structures, Man8-9GlcNAc2. In contrast, glyco-
sylation of gp41 is reflected by cell-specific processing and
dominated by complex-type glycans. Analysis of uncleaved
BG505 SOSIP.664 glycoproteins, as well as uncleaved gp140
oligomers from BG505 and other genotypes, revealed a much
higher degree of processing, which could be correlated with
more open and irregular Env configurations that, by extrapola-
tion, reduce the structural constraints on the relevant carbohy-
drate processing enzymes. Thus, the quaternary structure of
HIV-1 Env is, in itself, an important parameter in determining
how native trimers are glycosylated.
RESULTS
Protein-DirectedGlycosylation of gp120Subunits of Env
Trimers
BG505SOSIP.664 gp140 trimerswere expressed in stably trans-
fected Chinese hamster ovary (CHO) or 293T cells and purified
using a 2G12 bNAb-affinity column followed by size exclusion
chromatography (SEC), as previously described (Chung et al.,
2014). The CHO and 293T cell-derived trimers, purified by the
same method, had similar apparent molecular weights (Fig-
ure S1). When resolved by SDS-PAGE in the presence of the
reducing agent DTT, the gp120 and gp41ECTO domains were
fully separated, indicating that the gp140 proteins had been
appropriately cleaved by furin during expression (Figure S1).
The N-linked glycans were released from SDS-PAGE gel
bands by protein N-glycosidase F (PNGase F) digestion. The
gp140 band was derived from a non-reduced SDS-PAGE gel,
and the gp120 and gp41ECTO bands from a reduced gel. Isolated
glycans were fluorescently labeled with 2-aminobenzoic acid
(2-AA) and analyzed by hydrophilic interaction liquid chromatog-
raphy-ultra performance liquid chromatography (HILIC-UPLC)
(Figure 1). The peaks in the HILIC-UPLC profiles were assigned
by sequential digestion of the labeled glycanswith a panel of exo-
glycosidases (Figure S2; Table S1). The overall profiles of the
BG505 SOSIP.664 trimers from CHO and 293T cells were very
similar, with both containing a large population of oligomannose
glycans (Figure 1A). Integration of the chromatograms revealed
that oligomannose glycans accounted for 55% and 56% of thell Reports 11, 1604–1613, June 16, 2015 ª2015 The Authors 1605
Table 1. Abundances of Oligomannose Glycans in Different Env Proteins
Env Protein Producer Cell Affinity Purification Scheme
Abundance (% of Total Glycans)
M5a M6 M7 M8 M9 Total
gp120 BG505 from Cleaved Trimers
SOSIP.664 CHO PGT151 5 7 8 18 27 66
SOSIP.664 CHO PGT145 5 7 8 17 27 65
SOSIP.664 CHO 2G12 6 7 9 18 25 65
SOSIP.664 293T 2G12 4 4 6 15 34 63
SOSIP.664 293F 2G12 8 5 8 19 20 60
SOSIP.664 293F PGT151 9 5 8 24 25 71
gp41ECTO BG505 from Cleaved Trimers
SOSIP.664 CHO 2G12 3 8 5 2 1 19
SOSIP.664 293T 2G12 6 9 12 5 2 34
gp140 from Cleaved and Uncleaved Trimersb
SOSIP.664c CHO 2G12 6 8 8 14 20 55
SOSIP.664c 293T 2G12 5 5 8 13 25 56
BG505 WT.SEKSd 293T 2G12 6 5 8 12 11 42
CZA97.012d 293T Ni2+-NTA 10 4 7 7 3 30
CN54d CHO 5F3 7 4 6 6 3 27
UG37d CHO 5F3 9 4 5 10 14 42
aMx refers to ManxGlcNAc2 glycans.
bGlycan profiles for gp140 constructs include contributions from both gp120 and gp41ECTO domains.
cCleaved trimer.
dUncleaved trimer.total glycan population of the CHO and 293T-derived trimers,
respectively (Table 1). Man8GlcNAc2 and Man9GlcNAc2 forms
were particularly abundant, together representing 34% and
38% of the CHO and 293T-derived glycan pools, respectively.
Separation of the trimers into their constitutive subunits re-
vealed that glycans from gp120 accounted for the majority of
the overall gp140 profile, which is expected because 72 of
the total 84 potential glycosylation sites on BG505 gp140 are
located on the three gp120 subunits. The gp120 subunits from
CHO and 293T cell-derived BG505 SOSIP.664 trimers contained
65% and 63% oligomannose glycans, respectively (Figure 1B;
Table 1), with a comparable value (60%) for trimers expressed
in 293F cells (Figure S3; Table S2). Man8GlcNAc2 and Man9-
GlcNAc2 together accounted for up to 49% of total glycan con-
tent (Figure S3; Tables 1 and S2). In contrast, oligomannose gly-
cans were much less abundant on the gp41ECTO subunits (19%
and 34% for CHO and 293T cell-derived trimers, respectively).
The presence of a large population of complex-type glycans
on the gp41ECTO subunits revealed the impact of the producer
cell on glycosylation, with CHO cells generating more sialylated
structures than 293T cells (Figures 1C and S2; Table S2).
Thus, the two subunits of the trimer are processed differently,
with gp120 (60%–65%) having a higher oligomannose content
than gp41ECTO (19%–34%). A likely explanation is that process-
ing enzymes face greater restrictions when accessing gp120
because the local glycan density is so much greater compared
with gp41ECTO. Analysis of a crystal structure of the BG505
SOSIP.664 trimer (Pancera et al., 2014) reveals that the 72
gp120 glycosylation sites give rise to an average density of
one per1,000 A˚2 surface area; for the 12 predicted gp41 glyco-1606 Cell Reports 11, 1604–1613, June 16, 2015 ª2015 The Authorssylation sites, the corresponding value is one per 2,500 A˚2.
Whether such differential processing and the resulting glycan
composition differences are important for the function of the
two subunits is not yet known.
Significantly, membrane-associated, cleaved (but non-SOSIP
stabilized) BG505 EnvDCT trimers, extracted from the cell mem-
brane via PGT151 bNAb affinity purification (Blattner et al., 2014),
were also highly enriched for oligomannose glycans and had
a highly similar glycan profile to the comparable BG505
SOSIP.664 preparation (Figure S4). The similarity between the
glycan content of soluble and membrane-extracted Env trimers
therefore implies that the membrane does not confer additional
constraints on glycan processing and that the design and
methods used to create soluble SOSIP.664 trimers do not signif-
icantly impact the resulting glycosylation.
The Trimer Glycan Signature Is Independent of
Glycan-Specific bNAb Purification
Glycan-dependent bNAbs differ in their specificities for glycan
structures. We therefore sought to determine whether affinity
purification via a 2G12 column had affected the glycan profile
of the BG505 SOSIP.664 trimers analyzed above, by purifying
the trimers in different ways. While 2G12 is selective for terminal
Mana1/2Man on oligomannose glycans (Sanders et al., 2002;
Scanlan et al., 2002), the PGT145 and PGT151 epitopes include
complex glycans on the gp120 trimer apex and on gp41ECTO,
respectively (Blattner et al., 2014; Falkowska et al., 2014; McLel-
lan et al., 2011). Moreover, PGT145 and PGT151 recognize
quaternary structure-dependent epitopes that are present only
on fully native trimers (Blattner et al., 2014; Falkowska et al.,
Figure 2. Glycan Profiles of BG505 SOSIP.664 Trimers following
bNAb Affinity Purification
(A–C) CHO cell-derived trimers were purified by bNAb affinity chromatography
using 2G12, PGT145 or PGT151, followed by SEC. Glycans isolated from
reducing SDS-PAGE gel bands containing cleaved gp120 subunits were
analyzed by HILIC-UPLC. The various bNAb epitopes are colored light blue on
an EM reconstruction on the left. Peaks corresponding to oligomannose gly-
cans are colored in shades of green, and the corresponding peak areas are
illustrated in the associated pie charts, as in Figure 1. See also Figure S3.
Figure 3. Effect of Proteolytic Cleavage on Env Glycan Processing
His-tagged BG505 SOSIP.664 trimers were expressed in 293F cells with and
without furin co-expression and purified by Ni2+-NTA affinity chromatography.
(A) Reducing SDS-PAGE of trimers expressed without furin, and the resulting
HILIC-UPLC glycan profiles derived from gel bands corresponding to un-
cleaved gp140 (top) and cleaved gp120 (bottom).
(B) Reducing SDS-PAGE of the same trimers but co-expressed with furin, and
the corresponding HILIC-UPLC glycan profiles derived from the band corre-
sponding to cleaved gp120. Peaks corresponding to oligomannose glycans
are colored in shades of green, and the corresponding peak areas are illus-
trated in the associated pie charts, as in Figure 1. SDS-PAGE analysis (both
panels) reveals a minor population of low molecular weight contaminants.2014; McLellan et al., 2011; Pugach et al., 2015). We found that
trimers purified using PGT145, PGT151, and 2G12, in each case
followed by SEC, had almost identical glycosylation profiles (Fig-
ure 2). The same finding was made when a His-tagged BG505
SOSIP.664 trimer was expressed in 293F cells and affinity puri-
fied using various bNAbs (2G12, PGT151, PGT145, PG9, and
b12), after earlier Ni2+-affinity chromatography and SEC purifica-
tion (Figure S3; Table S2). Thus, irrespective of the bNAb used,
the affinity-purified trimers had a very similar proportion of oligo-
mannose glycans (60%–71%). The additional bNAb affinity puri-
fication step had little impact on the glycosylation profiles of the
Ni2+/SEC-purified BG505 SOSIP.664 trimers, which had a level
of oligomannose glycans comparable to that found after a
bNAb affinity purification step (Figure S3; Table S2).
The above findings strongly suggest that the observed domi-
nance of large oligomannose glycoforms is an integral feature
of the BG505 SOSIP.664 trimers, irrespective of the cell type
used for expression (CHO, 293T, 293F). Moreover, as bNAbs
with divergent glycan specificities (2G12, PGT151, PGT145,
PG9) or with less glycan-dependent epitopes (b12) all recognize
(i.e., purify) trimers that bear essentially indistinguishable glycan
profiles, the trimer population must be highly homogeneous andCeconsistently folded into a native conformation. Similar results
from His-tag purification (i.e., glycan independent) support this
conclusion.
Uncleaved Trimers Undergo Greater Levels of Glycan
Processing
An alternative approach to making soluble gp140 immunogens is
to eliminate the cleavage site between the gp120 and gp41ECTO
subunits (Go et al., 2014; Kovacs et al., 2012; Ringe et al.,
2013). The influence of furin cleavage on Env glycosylation is un-
known. To assess whether this design difference affects glycan
processing, we expressed His-tagged BG505 SOSIP.664 Env
proteins without co-transfecting the furin protease. Endogenous
furin is not sufficiently abundant to process all trimers transiting
through the secretory pathway. Thus, both uncleaved (i.e.,
gp140 band) and cleaved (gp120 band) Env species were
observed when SDS-PAGE was carried out under reducing con-
ditions (Figure 3A). Comparison of the glycan composition of the
gp140 and gp120 bands revealed remarkable differences; the
gp140 band contained a much greater content of processed gly-
cans than the gp120. The discrepancy was substantially greater
than could be accounted for by the gp41ECTO subunit, which is
present in the gp140 band but not the gp120 band (Figure 3A).ll Reports 11, 1604–1613, June 16, 2015 ª2015 The Authors 1607
Figure 4. Disordered Configurations of Uncleaved gp140s Are
Associated with Higher Levels of Glycan Processing
(A) HILIC-UPLC glycan data and 2D class averages from negative stain EM
analysis are shown for BG505 SOSIP.664 trimers expressed in 293T cells and
purified using 2G12-affinity chromatography followed by SEC. The UPLC
chromatogram is reproduced from Figure 1A to facilitate data comparison.
(B) Uncleaved BG505WT.SEKS gp140 expressed in 293T cells and purified by
2G12 affinity chromatography followed by SEC. Quantitation of the complete
datasets shows that native-like, regular, and compact trimers constitute >90%
of the images of the BG505 SOSIP.664 proteins. In contrast, <5% of the un-
cleaved BG505 WT.SEKS proteins are in native-like form, where the pre-
dominant images represent disordered, splayed out trimers.
(C–E) The same is also true of (C) uncleaved, His-tagged CZA97.012 gp140
proteins produced in 293T cells and purified by Ni2+-NTA affinity chromatog-
raphy followed by SEC; (D) uncleavedUG37 gp140; (E) uncleavedCN54 gp140
proteins (the latter two purchased from Polymun Scientific). Peaks corre-
sponding to oligomannose glycans are colored in shades of green, and the
corresponding peak areas are illustrated in the associated pie charts, as in
Figure 1.When furin was co-expressed with the same His-tagged BG505
SOSIP.664construct, all the trimerswere fully cleaved (Figure3B).
The glycan profile of the resulting SDS-PAGE gp120 band was
highly similar to the corresponding band derived when endoge-
nous furin cleavedonly a subset of the trimers. Thus, co-transfect-
ing furin with SOSIP.664 trimers does not adversely affect trimer
glycosylation and, in fact, emulated natural cleavage. Moreover,
cleavage by furin, whether endogenous or transfected, is suffi-
cient to create a distinct oligomannose glycoform.
The Env Quaternary Structure Correlates with the
Degree of Glycan Processing
To investigate why cleaved and uncleaved BG505 SOSIP.664
gp140s have such different glycan compositions, we used nega-
tive stain electron microscopy (EM) to visualize their configura-1608 Cell Reports 11, 1604–1613, June 16, 2015 ª2015 The Authorstions (Figure 4). The fully cleaved BG505 SOSIP.664 proteins
form regular, homogeneous trimers with a characteristic propel-
ler-like appearance (Figure 4A), which is consistent with previous
studies (Chung et al., 2014; Ringe et al., 2013). The bNAb used
for affinity purification did not affect the appearance of these tri-
mers (data not shown). For comparison, we used the BG505
WT.SEKS gp140 protein, which has an identical sequence to
the BG505 SOSIP.664 construct except that the furin cleavage
site is inactivated (RRRRRR to SEKS) and the stabilizing SOSIP
mutations are not included (Ringe et al., 2013). Similar to the ob-
servations of the uncleaved BG505 SOSIP.664 subpopulation
(see above), the glycans on the uncleaved BG505 WT.SEKS
gp140 were more highly processed than on their cleaved coun-
terparts; oligomannose structures accounted for only 42%of the
total glycan population, with Man8GlcNAc2 and Man9GlcNAc2
accounting for just 23% (Figure 4B; Table 1). When viewed by
EM, the uncleaved BG505WT.SEKS gp140 glycoproteins adop-
ted irregular, non-native, and heterogeneous configurations in
which the gp120 subunits were frequently splayed out (Fig-
ure 4B). These images are inmarked contrast to the closed forms
of the cleaved BG505 SOSIP.664 trimers and are consistent with
previous studies of several other uncleaved gp140 proteins
(Georgiev et al., 2015; Moscoso et al., 2014; Ringe et al., 2013;
Tran et al., 2014).
A similar correlation between quaternary structure and glycan
profile was also observed when analyzing further vaccine-rele-
vant gp140 glycoproteins from different clades. The CZA97.012
protein derives from a subtypeC sequence and has been studied
in multiple immunization and other experiments (Go et al., 2014;
Kovacs et al., 2012; Nkolola et al., 2010). Like the BG505
WT.SEKS gp140, it has a knocked-out cleavage site, but also in-
cludes foldon domains near the C-termini of the gp41ECTO sub-
units to artificially drive oligomerization (Go et al., 2014; Kovacs
et al., 2012; Nkolola et al., 2010). The CZA97.012 gp140 was ex-
pressed in 293T cells and purified via its C-terminal His-tag fol-
lowed by SEC, as previously described (Chung et al., 2014).
The glycan composition of the SEC fraction corresponding to
a protein with three gp120 and three gp41ECTO subunits was
then determined (Figure 4C). This gp140 population contained
only 30% oligomannose, with just 10% of the glycans in
Man8GlcNAc2 or Man9GlcNAc2 form. Once again, the EM anal-
ysis revealed that most of these gp140s adopt a splayed-open
conformation, with only a small fraction of particles (<10%) hav-
ing a more compact appearance (Figure 4C). Similar EM results
were also observed with two other uncleaved, foldon-containing
glycoproteins, CN54 gp140 (clade C) and UG37 gp140 (clade A),
which have also been investigated as candidate immunogens
(Lewis et al., 2011, 2014; Schiffner et al., 2013). These gp140s
were also predominantly irregularly shaped (Figures 4D and
4E), as described previously (Ringe et al., 2013). The observed
disorder of the CN54 and UG37 gp140s again correlated with a
high degree of glycan processing, the oligomannose content be-
ing 27% and 42%, respectively (Figures 4D and 4E; Table 1).
DISCUSSION
Oligomannose glycans, which are co-translationally added to
glycoproteins, are typically efficiently processed to complex
Figure 5. Env Cleavage Induces Highly Homogeneous Glycoforms
Dominated by Oligomannose Glycans
Env is synthesized as a gp160 precursor in the ER, and oligomannose-type
glycans are incorporated at glycosylation sequons: Asn-X-Ser/Thr (where X is
any amino acid except Pro). As glycoproteins pass through the secretory
pathway, they are exposed to a-mannosidases and other glycan processing
enzymes, which normally convert oligomannose-type glycans (green) to
complex-type glycans (gray). The quaternary structure of Env dictates how
well processing enzymes can access the glycans on gp120. Cleaved Env
exhibits a compact quaternary structure that prevents trimming by ER and
Golgi a-mannosidases and is thus secreted as an oligomannose-dominated
glycoform. In contrast, uncleaved Env has a more open and irregular structure
that facilitates easier access by processing enzymes, leading to conversion of
the majority of the oligomannose glycans to more complex-type structures.
However, high glycan density on the outer domain of gp120 creates a region
that is largely protected from a-mannosidase trimming, known as the IMP,
which is present on both cleaved and uncleaved Env. Gp41 is more accessible
to processing enzymes than gp120 and is dominated by complex-type
glycosylation.structures. The presence of oligomannose-type glycans on
mature, native HIV-1 Env glycoproteins represents a divergence
from this default pathway of ‘‘self’’ glycosylation and provides a
potential window for immune recognition. Indeed, many potent
bNAbs are glycan reactive (Blattner et al., 2014; Falkowska
et al., 2014; Garces et al., 2014; Huang et al., 2014; Kong
et al., 2013; McLellan et al., 2011; Mouquet et al., 2012; Pancera
et al., 2013; Pejchal et al., 2011; Sanders et al., 2002; Scanlan
et al., 2002; Scharf et al., 2014; Walker et al., 2009,
2011). The first described, 2G12, binds only to the terminal
Mana1/2Man moieties of oligomannose glycans (Scanlan
et al., 2002), while bNAbs such as the PGT series involve
contacts with both glycans and protein (Blattner et al., 2014;
Falkowska et al., 2014; Garces et al., 2014; Huang et al., 2014;
Kong et al., 2013; McLellan et al., 2011; Mouquet et al., 2012;
Pancera et al., 2013; Pejchal et al., 2011; Scharf et al., 2014;
Walker et al., 2009, 2011). Overall, there is now widespread
appreciation that vaccine candidates intended to induce
bNAbs should have a glycan profile that mimics what is present
on native Env trimers (Bonomelli et al., 2011; Burton et al.,Ce2012; Crispin and Bowden, 2013; Doores et al., 2010; Dunlop
et al., 2010).
BG505 SOSIP.664 trimers are highly stable and homogeneous,
have native-like antigenic properties, and resemble viral Env
when viewed by negative stain EM (Ringe et al., 2013; Sanders
et al., 2013; Yasmeen et al., 2014). Although their EM and crystal
structures have been determined, it was not possible to define the
processing state of the glycans from the density maps (Julien
et al., 2013; Lyumkis et al., 2013; Pancera et al., 2014). Here,
we found that the gp120 subunits of the same SOSIP.664 trimers
have a large oligomannose content, consistent with previous re-
ports of virion-derived Env (Bonomelli et al., 2011; Doores et al.,
2010). The distribution of oligomannose glycans throughout
the Man5-9GlcNAc2 series was particularly notable, with Man8-
GlcNAc2 and Man9GlcNAc2 structures accounting for up to half
of the glycan population. Presumably, their existence reflects pro-
tection from a-mannosidase processing that arises through the
stabilization and conformational restrictions created by a network
of glycan-glycan interactions that extend across the gp120 sub-
units of the trimer. These structural constraints are the primary
determinant of Env glycosylation, and they create a reproducible
glycan profile irrespective of the producer cell. In contrast, the
lack of such constraints on the gp41ECTO subunits results in a
greater dependency on the producer cell in determining the final
glycan profile. The low abundance of oligomannose structures
observed on gp41ECTO subunits here is consistent with the previ-
ously reported resistance of virion-derived trimeric gp41 to Endo
H processing (Crooks et al., 2011).
Further support for structure-driven glycan processing on the
native trimer comes from analysis of uncleaved gp140 proteins.
EM images of these proteins generally show three separated
gp120 subunits dangling from a central gp41ECTO moiety to
which they remain tethered by the uncleaved inter-subunit link-
age (Georgiev et al., 2015; Moscoso et al., 2014; Ringe et al.,
2013; Tran et al., 2014), a conclusion strongly supported by
hydrogen deuterium exchange-mass spectrometry (HDX-MS)
and surface plasmon resonance (SPR) data (Guttman et al.,
2014; Ringe et al., 2013; Yasmeen et al., 2014). The EM images
of uncleaved gp140s shown here are entirely consistent, with
irregularly shaped forms predominating. These more open con-
figurations are reflected in their glycosylation profiles, which
display a high degree of processing; in particular, there is amark-
edly lower abundance ofMan8GlcNAc2 andMan9GlcNAc2 struc-
tures. A prior report of the highly processed nature of the glycans
on uncleaved gp140 proteins from various genotypes including
CZA97.012 attributed the finding to the use of non-lymphoid
cells as a production substrate for recombinant proteins (Go
et al., 2014). Our results show that this is not the explanation;
BG505 SOSIP.664 trimers produced in both CHO and 293T cells
bear the high-oligomannose characteristic of Env trimers derived
from viruses produced in lymphoid cells (Bonomelli et al., 2011;
Doores et al., 2010). Instead, we show conclusively that whether
the BG505 SOSIP.664 gp140 protein is furin cleaved or not,
and hence whether it does or does not adopt a native-like
conformation, is the paramount factor on whether the majority
of the gp120 subunit glycans remain in the oligomannose form
or are processed (Figure 5). An extension to the above findings
and conclusions is that the folding and oligomerization of thell Reports 11, 1604–1613, June 16, 2015 ª2015 The Authors 1609
furin-cleaved trimers must occur quickly enough in the Golgi
apparatus to protect against significant a-mannosidase pro-
cessing. Overall, the localization of furin activity and the action
of Golgi a-mannosidases are critical factors that shape how
the trimers are glycosylated.
The glycosylation of BG505 SOSIP.664 trimers was surpris-
ingly homogeneous. Indeed, Ni2+-affinity purification of His-
tagged trimers followed by SEC was sufficient to isolate a trimer
population with a native-like glycosylation profile, comparable to
that achieved using bNAb-affinity columns. We caution, how-
ever, that this conclusion is highly unlikely to be generalizable
to all SOSIP.664 trimer preparations based on different geno-
types. In particular, if non-native, misfolded trimers are present
(which is not the case with BG505), they will be co-purified
with properly folded trimers when a Ni2+/SEC protocol is used.
In contrast, a bNAb column eliminates such unwanted contami-
nants, particularly when a trimer-specific bNAb such as PGT145
is used (Pugach et al., 2015).
The homogeneity of BG505 SOSIP.664 trimers has impli-
cations for developing vaccine strategies aimed at inducing
glycan-dependent or glycan-avoiding bNAbs (Garces et al.,
2014). Previous studies have suggested that the majority of
Env glycans are highly processed (Go et al., 2014; Pabst et al.,
2012). The resulting complexity could be construed to constitute
a barrier against the elicitation of glycan-dependent bNAbs
because the target epitope is diluted. However, the predomi-
nance of oligomannose-type glycans on all BG505 SOSIP.664
glycoforms reduces or even eliminates such concerns.
In summary, native-like BG505 SOSIP.664 trimers display a
glycosylation profile dominated by oligomannose-type glycans
and, in particular, large Man8GlcNAc2 and Man9GlcNAc2 struc-
tures. In contrast, uncleaved gp140s lack these key properties
due to their non-native structures and the resulting loss of steric
constraints on glycan-processing enzymes. Do the elevated
levels of oligomannose glycans on the Env trimer have some
functional role, for example, in viral tropism and in the infection
process? Although we cannot answer that question yet with
any certainty, we suggest that these structures arose because
HIV-1 requires a high density of Env glycans to protect underly-
ing, vulnerable, conserved protein epitopes. Oligomannose gly-
cans may also play a role in tropism by allowing HIV-1 to interact
with cell surface lectins such as DC-SIGN (Feinberg et al., 2001;
Geijtenbeek et al., 2000). Irrespective of their genesis, the oligo-
mannose components of the glycan shield constitute an Achilles’
heel on the virus that can be exploited for vaccine design.EXPERIMENTAL PROCEDURES
Env Trimer Expression and Purification
BG505 SOSIP.664 trimers were expressed in stable Flp-In 293T and CHO cells
and purified by 2G12-affinity chromatography (unless stated otherwise) fol-
lowedbySECto removemonomersanddimers, asdescribedelsewhere (Chung
et al., 2014). Additionally, BG505 SOSIP.664 constructs bearing a C-terminal
His-tag were expressed in 293F cells as previously described (Sanders et al.,
2013). These Env proteins were purified from the culture supernatants by Ni2+-
NTA affinity columns, followed by SEC. The trimer fraction was then used for
subsequent bNAb-affinity purifications. Affinity columns were made using a
CNBr-activated Sepharose 4B resin (GE Healthcare) as previously described
(Sanders et al., 2013). Antibodies used to make the affinity columns were ex-1610 Cell Reports 11, 1604–1613, June 16, 2015 ª2015 The Authorspressed in 293F cells and purified using Protein A affinity chromatography ac-
cording to the manufacturer’s instructions (GE Healthcare). For bNAb-affinity
purification of the trimers, the binding buffer was 500 mM NaCl, 20 mM Tris-
HCl (pH 8); the wash buffer was 20 mM Tris-HCl, 500 mM NaCl (pH 8), and the
trimers were eluted with 3MMgCl2. The eluted trimers were immediately buffer
exchanged into 10 mM Tris-HCl, 75 mM NaCl (pH 8) and concentrated using a
50 kDa cut-off Vivaspin column (GE Healthcare). A His-tagged BG505
SOSIP.664 N332A mutant was generated by site-directed mutagenesis, ex-
pressed in 293F cells, andpurifiedbyPGT151-affinity chromatography followed
by SEC. Cleaved BG505 EnvDCT trimers were expressed in 293F cells and
purified by PGT151-affinity chromatography followed by SEC, as previously
described (Blattner et al., 2014). Where the role of furin-cleavage was investi-
gated, His-tagged BG505 SOSIP.664 was expressed in 293F cells with and
without recombinant furin, and the resulting glycoproteins were purified by
Ni2+-NTA affinity chromatography. BG505 WT.SEKS uncleaved gp140 was
expressed in 293T cells and purified by 2G12-affinity chromatography followed
by SEC, as previously reported (Chung et al., 2014; Ringe et al., 2013; Yasmeen
et al., 2014).His-tagged, uncleavedCZA97.012gp140waspurified byNi2+-NTA
affinity chromatography followedbySEC, as previously described (Chung et al.,
2014; Go et al., 2014; Kovacs et al., 2012). The uncleaved CN54 gp140
(from clade C strain 97CN001, accession number GenBank: AF286226) and
UG37 gp140 (from clade A strain 92/UG/037, accession number GenBank:
AY494974)proteinswerepurchasedfromPolymunScientific.Theseproteinsare
described in datasheets accessible from http://www.polymun.at and are
purified using the anti-gp41 antibody 5F3, followed by ion-exchange
chromatography.
Enzymatic Release of N-Linked Glycans
Env trimers (10 mg), purified in various ways, were fractionated by SDS-PAGE,
with and without the addition of DTT, and the gels were stained with Coomas-
sie blue. Bands corresponding to the gp140, gp120, or gp41ECTO species were
excised from the gels and washed alternately with acetonitrile and water five
times. N-linked glycans were then released by addition of PNGase F at
5,000 U/ml and incubation at 37C for 16 hr, according to the manufacturer’s
instructions (NEB; New England Biolabs). The released glycans were subse-
quently eluted from gel bands by extensive washing with water and then dried
using a SpeedVac concentrator.
Fluorescent Labeling of N-Linked Glycans
Released glycans were labeled with 2-AA as previously described (Neville
et al., 2009). Briefly, glycans were resuspended in 30 ml of water followed by
addition of 80 ml of labeling mixture (30 mg/ml 2-AA and 45 mg/ml sodium cy-
anoborohydride in a solution of sodium acetate trihydrate [4% w/v] and boric
acid [2% w/v] in methanol). Samples were then incubated at 80C for 1 hr.
Excess label was removed using Spe-ed Amide-2 cartridges, as previously
described (Neville et al., 2009).
HILIC-UPLC
Fluorescently labeled glycans were resolved by HILIC-UPLC using a 2.1mm3
10 mm Acquity BEH Amide Column (1.7 mm particle size) (Waters). The
following gradient was run: time = 0 min (t = 0): 22.0% A, 78.0% B (flow rate
of 0.5 ml/min); t = 38.5: 44.1% A, 55.9% B (0.5 ml/min); t = 39.5: 100% A,
0% B (0.25 ml/min); t = 44.5: 100% A, 0% B (0.25 ml/min); t = 46.5:
22.0% A, 78.0% B (0.5 ml/min), t = 48: 22.0% A, 78.0% B (0.5 ml/min), where
solvent A was 50 mM ammonium formate (pH 4.4) and solvent B was acetoni-
trile. Fluorescence was measured using an excitation wavelength of 250 nm
and a detection wavelength of 428 nm. Data processing was performed using
Empower 3 software. The percentage abundance of oligomannose-type gly-
cans was calculated by integration of the relevant peak areas before and after
Endo H digestion, following normalization.
Exoglycosidase Sequencing of N-Linked Glycans
The structures of N-linked glycans were determined by sequential digestion
of labeled glycans with a panel of exoglycosidases. The enzymes used were
neuraminidase from Clostridium perfringens (NEB), a-L-fucosidase from
bovine kidney (Sigma), b1,4-galactosidase from Streptococcus pneumoniae,
b-N-acetylglucosaminidase from S. pneumonia, and a(1-2,3,6)-mannosidase
from Jack bean (QA Bio). Endoglycosidase H (NEB) was used for quantitation
of oligomannose structures. Digestions were performed at 37C for 16 hr, ac-
cording to manufacturers’ instructions. The digested glycans were purified us-
ing a polyvinylidene fluoride (PVDF) protein-bindingmembrane plate (Millipore)
prior to HILIC-UPLC analysis.
Negative Stain EM
Env proteins were prepared for negative stain EM analysis as previously
described (Pugach et al., 2015; Ringe et al., 2013; Sanders et al., 2013). Briefly,
a 3 ml aliquot containing 0.03 mg/ml of Env protein was applied for 5 s onto a
carbon-coated 400 Cu mesh grid that had been glow discharged at 20 mA for
30 s and then negatively stained with 2% (w/v) uranyl formate for 60 s. Data
were collected using an FEI Tecnai T12 electron microscope operating at 120
keV, with an electron dose of25 e/A˚2 and amagnification of 52,0003 that re-
sulted inapixel sizeof2.05 A˚at the specimenplane. Imageswereacquiredwitha
Tietz TemCam-F416 CMOS camera using a nominal defocus range of 1000 nm.
Data processing methods were adapted from those used previously (Pu-
gach et al., 2015; Ringe et al., 2013; Sanders et al., 2013). In summary, the
Appion software package (Voss et al., 2009) was used to automatically pick
particles, create stacks, and calculate reference-free 2D class averages with
iterative MSA/MRA (Ogura et al., 2003). The 2D class averages were visually
inspected and the classes were segregated into one of three structural groups
labeled ‘‘closed,’’ ‘‘open,’’ or ‘‘non-native’’ as described previously (Pugach
et al., 2015). The amount of native-like particles was defined as the sum of
‘‘closed’’ and ‘‘open’’ particles.
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